![](/images/graphics-bg.png)
Compound Kushen Injection as an Adjunctive Therapy for the Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
Joint Authors
Chen, Weihao
Zhang, Yimin
Pu, Liu
Cao, Lu-xi
Wu, Kun-ji
Chen, Shu-lian
Lin, Ji-huan
Li, Cheng-lu
Wang, Shi-qi
Zhu, Ming-min
Source
Evidence-Based Complementary and Alternative Medicine
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-11, 11 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-11-06
Country of Publication
Egypt
No. of Pages
11
Main Subjects
Abstract EN
Objectives.
To evaluate the efficacy and safety of compound Kushen injection (CKI) combined with chemo treatment (chemo) for non-small-cell lung cancer (NSCLC).
Methods.
We systematically searched the literature published in seven databases, including Embase, PubMed, central, MEDLINE, CNKI, Wanfang, and VIP, from their inception to April 2019 for all randomized controlled trials (RCTs) comparing CKI plus chemo with chemo alone in patients with NSCLC.
Our main end point was clinical efficiency and the secondary outcomes were Karnofsky performance score (KPS), immune function, and adverse events.
The Cochrane risk of bias tool was applied for quality assessment.
Results.
10 studies involving 1019 participants were included.
The clinical response rate (relative risk (RR) = 1.21, 95% confidence interval (CI): 1.06 to 1.37; P=0.003), KPS (RR = 2.18, 95% CI: 1.49 to 3.17; P<0.0001), immune function (mean differences (MD) = 0.82, 95% CI: 0.12 to 1.52; P=0.02) and adverse effects (RR = 0.67, 95% CI: 0.60 to 0.74; P<0.00001) in the CKI plus chemo group showed significant differences when compared with chemo alone.
Conclusions.
CKI combined with chemo can improve clinical efficiency, KPS, and immune function and reduce adverse reactions in patients with NSCLC when compared with chemo alone.
However, more rigorously designed RCTs are needed to validate this benefit, as some of the included RCTs are of low methodological quality.
American Psychological Association (APA)
Pu, Liu& Chen, Weihao& Cao, Lu-xi& Wu, Kun-ji& Chen, Shu-lian& Lin, Ji-huan…[et al.]. 2019. Compound Kushen Injection as an Adjunctive Therapy for the Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. Evidence-Based Complementary and Alternative Medicine،Vol. 2019, no. 2019, pp.1-11.
https://search.emarefa.net/detail/BIM-1150769
Modern Language Association (MLA)
Pu, Liu…[et al.]. Compound Kushen Injection as an Adjunctive Therapy for the Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. Evidence-Based Complementary and Alternative Medicine No. 2019 (2019), pp.1-11.
https://search.emarefa.net/detail/BIM-1150769
American Medical Association (AMA)
Pu, Liu& Chen, Weihao& Cao, Lu-xi& Wu, Kun-ji& Chen, Shu-lian& Lin, Ji-huan…[et al.]. Compound Kushen Injection as an Adjunctive Therapy for the Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. Evidence-Based Complementary and Alternative Medicine. 2019. Vol. 2019, no. 2019, pp.1-11.
https://search.emarefa.net/detail/BIM-1150769
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1150769